ALGENICS is a privately-held biotechnology company founded in 2008 as a spin-off from The French Research Institute for Exploitation of the Sea (IFREMER). The company operates its own facility in Saint Herblain/Nantes (France).
We focus on innovative uses of microalgae to produce recombinant biotherapeutics. Our technological platform Algebiosys™ encompasses tools and technologies to efficiently generate stable strains of highly-productive microalgal cells. This proprietary and patented platform allows the biomanufacturing of a broad range of therapeutics in our PTA cell line including complex multimeric glycoproteins.
Our strategy is to identify and produce biotherapeutics that benefit from our technology at the level of industrial proof of concept. Current targets include secreted antibodies, viral envelope antigens and enzymes for replacement therapy in lysosomal storage diseases.